Fair Value Calculator Fair Value Calculator
EN DE

Phaarmasia Limited (523620) Fair Value & Analysis

Other · IN · Market cap ₹192M

PL Phaarmasia Limited 523620 · BSE
Price₹99.23
Fair Value₹97.10
Upside-2.1%
Quality75/100
Watch Phaarmasia Limited for free — get notified when fair value or trend changes. Watch for free
Evidence: Medium Range ₹72.83 – ₹121.38

Fair value as of: Jul 4, 2026

From 14 valuation models · updated today

Share price +24.8% over the past month.

Price vs Fair Value (12 months)

₹129.20 ₹26.40 Fair Value ₹97.10 May 2025 Jul 2026

12‑month range ₹26.40 – ₹129.20 · fair‑value band ₹72.83 – ₹121.38 · the ₹99.23 price screens above the ₹97.10 fair value. As of Jul 4, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Phaarmasia Limited (523620) currently trades at ₹99.23, while our model-based Fair Value estimate is ₹97.10 — implying the stock looks roughly 2.1% overvalued today. We read business quality at 75/100 (high quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, Phaarmasia Limited generated revenue of ₹215M at a net margin of 3.3%. Revenue declined 36.4% year over year. Net debt stands at ₹8.0M. The stock trades on a trailing P/E of 27.9. Fundamentals as of Jul 4, 2026

Key figures & financial health

Revenue (TTM) ₹215M
Revenue growth (YoY) -36.4%
Net margin 3.3%
Free cash flow −₹164M FY2026
P/E ratio 27.9
Operating margin 4.4%
More key figures
EPS (TTM) ₹1.03
Net debt ₹8.0M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.

About the company

Phaarmasia Limited manufactures and sells pharmaceutical products in India and internationally. It offers cosmetics, toothpastes, and oral contraceptive pills. The company was incorporated in 1981 and is based in Hyderabad, India.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Phaarmasia Limited reported revenue of ₹472M in FY2026 versus ₹177M in FY2022, a compound +27.8%/yr. Reported net income was ₹176M in FY2026.

Revenue +27.8%/yr
FY22 ₹177M
FY23 ₹275M
FY24 ₹306M
FY25 ₹244M
FY26 ₹472M
Net income
FY22 −₹15.5M
FY23 −₹12.6M
FY24 −₹5.2M
FY25 −₹15.9M
FY26 ₹176M

Is 523620 fairly valued? → Check now

Similar stocks

6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).

Stock Price Fair Value vs Fair Value
There MOH €521.90 €209.16 -60%
Sony Corporation SON1 €17.58 €39.38 +124%
Federal Home Loan Mortgage Corporation FREJO $16.84 $28.75 +71%
533278 533278 ₹438.60 ₹720.31 +64%
Nestl?? India Limited 500790 ₹1,459 ₹279.60 -81%
540376 540376 ₹3,993 ₹1,806 -55%

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Phaarmasia Limited (523620) undervalued?
As of Jul 4, 2026, our model estimates a fair value of ₹97.10 versus a price of ₹99.23 — about −2% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 523620?
Our model-based fair value for Phaarmasia Limited is ₹97.10 (as of Jul 4, 2026), built from audited fundamentals. The current price is ₹99.23.
What is the quality score of 523620?
Phaarmasia Limited has a Quality Score of 75/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of Phaarmasia Limited (523620)?
Phaarmasia Limited reported trailing-twelve-month revenue of about ₹215M (latest available figure, as of Jul 4, 2026).
What is the net profit margin of 523620?
The net profit margin of Phaarmasia Limited is about 3.3%, meaning it keeps roughly 3.3% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.